11.67 USD
▼+0.17-6.04%
盘后 12.54 +0.97%
2026-08-03
市值
$978.43M
市盈率
—
EPS
-3.51
股息率
—
52 周区间
9.40 – 19.11
成交量
2.93M
Beta
1.74
目标价
40.50
52W 低 9.4052W 高 19.11
价格走势
公司简介
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet ...